Evotec Investor Presentation Deck

evotec PAGE 29 Academia & BRIDGES External deal- flow Partners Starting points to fuel EVO equity portfolio Portfolio companies C EVO equity EVO equity accelerates co-owning strategy Operational VC model - diversified portfolio with multiple shots on goal Evotec spin- outs Attractive portfolio with significant upside At Equity Holding (≥20%) or Significant influence Eternygen celmatix therapeutics BIOCAPITAL Minority Shareholdings (<20%) Carrick BRIDGES .... Topas Therapeutics mission Cajal Neuroscience LAB282 DARK BLUE https://actionplan.evotec.com/evoequity THERAPEUTICS Exscientia LAB150 facio AUTOBAHN therapies LABS CUREXSYS PURE 8 CURE AUTOBAHN FORGE Therapeutics a LABS DANUBE LABS FIBROCOR panCELLa BLACKSMITH ARGOBIO Immunitas THERAPEUTICS Medicines STUDIO AeoVian PHARMACEUTICALS ARGOBIO STUDIO BREAKPOINT THERAPEUTICS QUANTR oxvax Therapeutics TUBULIS IMIDomics Ananke Therapeutics beLAB2122 NephThera LEON ENABLING NANO NOW Centauri THERAPEUTICS Sernova Corp beLAB1407

View entire presentation